BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Klitgaard T, Nielsen TG. Overview of the human pharmacokinetics of recombinant activated factor VII. Br J Clin Pharmacol 2008;65:3-11. [PMID: 17961193 DOI: 10.1111/j.1365-2125.2007.03030.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Guzzetta NA, Huch S, Fernandez JD, Tosone SR, Miller BE. Use of recombinant factor VIIa for uncontrolled bleeding in neonates after cardiopulmonary bypass. Pediatric Anesthesia 2009;19:364-70. [DOI: 10.1111/j.1460-9592.2008.02905.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
2 Lee D, Nayak S, Martin SW, Heatherington AC, Vicini P, Hua F. A quantitative systems pharmacology model of blood coagulation network describes in vivo biomarker changes in non-bleeding subjects. J Thromb Haemost 2016;14:2430-45. [PMID: 27666750 DOI: 10.1111/jth.13515] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
3 Othman M, Powell S, Hopman WM, Lillicrap D. Variability of thromboelastographic responses following the administration of rFVIIa to haemophilia A dogs supports the individualization of therapy with a global test of haemostasis: TEG MONITORING AND INDIVIDUALIZATION OF rFVIIa THERAPY. Haemophilia 2010;16:919-25. [DOI: 10.1111/j.1365-2516.2010.02336.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
4 Zollner S, Schuermann D, Raquet E, Mueller-Cohrs J, Weimer T, Pragst I, Dickneite G, Schulte S. Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP). J Thromb Haemost 2014;12:220-8. [PMID: 24641308 DOI: 10.1111/jth.12477] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
5 Mesleh Shayeb A, Su Y, Kang G, Elbahlawan L, Reiss UM. Efficacy and Safety of Recombinant Activated Factor VII Off-label Use in a Pediatric Hematology/Oncology Cohort. J Pediatr Hematol Oncol 2019;41:e72-8. [PMID: 30608491 DOI: 10.1097/MPH.0000000000001379] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Møss J, Rosholm A, Laurén A. Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects. J Thromb Haemost 2011;9:1368-74. [PMID: 21575130 DOI: 10.1111/j.1538-7836.2011.04344.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
7 Jarosz K, Czupryńska M, Andrzejewska J, Wasilewicz MP, Post M, Lubikowski J, Wójcicki M, Milkiewicz P. Administration of a recombinant factor Vlla in patients undergoing liver transplantation for fulminant hepatic failure. Transplant Proc 2009;41:3088-90. [PMID: 19857684 DOI: 10.1016/j.transproceed.2009.07.099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
8 Golor G, Bensen‐kennedy D, Haffner S, Easton R, Jung K, Moises T, Lawo J, Joch C, Veldman A. Safety and pharmacokinetics of a recombinant fusion protein linking coagulation factor VIIa with albumin in healthy volunteers. J Thromb Haemost 2013;11:1977-85. [DOI: 10.1111/jth.12409] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
9 Morfini M. Rapid rFVIIa enhanced on-demand dosing in haemophilia inhibitor patients. Eur J Haematol 2016;96:111-8. [PMID: 26172449 DOI: 10.1111/ejh.12631] [Reference Citation Analysis]
10 Goel A, Nair SC, Viswabandya A, Masilamani VP, Rao SV, George A, Regi A, Jose R, Zachariah U, Subramani K, Eapen CE, Chandy G. Preliminary experience with use of recombinant activated factor VII to control postpartum hemorrhage in acute fatty liver of pregnancy and other pregnancy-related liver disorders. Indian J Gastroenterol 2013;32:268-71. [PMID: 23475547 DOI: 10.1007/s12664-013-0315-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
11 Margaritis P, Roy E, Aljamali MN, Downey HD, Giger U, Zhou S, Merricks E, Dillow A, Ezban M, Nichols TC, High KA. Successful treatment of canine hemophilia by continuous expression of canine FVIIa. Blood 2009;113:3682-9. [PMID: 19109232 DOI: 10.1182/blood-2008-07-168377] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 4.1] [Reference Citation Analysis]
12 Powell JS, Apte S, Chambost H, Hermans C, Jackson S, Josephson NC, Mahlangu JN, Ozelo MC, Peerlinck K, Pasi J, Perry D, Ragni MV, Wang X, Jiang H, Li S, Cristiano LM, Innes A, Nugent K, Brennan A, Luk A, Allen G, Pierce GF, Robinson B. Long‐acting recombinant factor IX Fc fusion protein ( rFIXF c) for perioperative management of subjects with haemophilia B in the phase 3 B‐LONG study. Br J Haematol 2015;168:124-34. [DOI: 10.1111/bjh.13112] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
13 Mahmood I. Designing first-in-human dose of coagulation factors: application of pharmacokinetic allometric scaling. Haemophilia 2014;20:32-8. [PMID: 23855969 DOI: 10.1111/hae.12231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
14 Shapiro AD, Hedner U. Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomes. Ther Adv Drug Saf 2011;2:213-25. [PMID: 25083214 DOI: 10.1177/2042098611415566] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
15 Persson E, Bolt G, Steenstrup TD, Ezban M. Recombinant coagulation factor VIIa – from molecular to clinical aspects of a versatile haemostatic agent. Thrombosis Research 2010;125:483-9. [DOI: 10.1016/j.thromres.2009.11.027] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
16 Agersø H, Brophy DF, Pelzer H, Martin EJ, Carr M, Hedner U, Ezban M. Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patients. J Thromb Haemost 2011;9:333-8. [PMID: 21114621 DOI: 10.1111/j.1538-7836.2010.04152.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
17 Karpf DM, Sørensen BB, Hermit MB, Holmberg HL, Tranholm M, Bysted BV, Groth AV, Bjørn SE, Stennicke HR. Prolonged half-life of glycoPEGylated rFVIIa variants compared to native rFVIIa. Thromb Res 2011;128:191-5. [PMID: 21429564 DOI: 10.1016/j.thromres.2011.02.018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
18 Brophy DF, Martin EJ, Christian Barrett J, Nolte ME, Kuhn JG, Gerk PM, Carr ME, Pelzer H, Agersø H, Ezban M, Hedner U. Monitoring rFVIIa 90 μg kg⁻¹ dosing in haemophiliacs: comparing laboratory response using various whole blood assays over 6 h. Haemophilia 2011;17:e949-57. [PMID: 21362113 DOI: 10.1111/j.1365-2516.2011.02492.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
19 Lau P, Ong V, Tan WT, Koh PL, Hartman M. Use of Activated Recombinant Factor VII in Severe Bleeding - Evidence for Efficacy and Safety in Trauma, Postpartum Hemorrhage, Cardiac Surgery, and Gastrointestinal Bleeding. Transfus Med Hemother 2012;39:139-50. [PMID: 22670132 DOI: 10.1159/000338034] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
20 Hardy J, Bélisle S, Van der Linden P. Efficacy and Safety of Recombinant Activated Factor VII to Control Bleeding in Nonhemophiliac Patients: A Review of 17 Randomized Controlled Trials. The Annals of Thoracic Surgery 2008;86:1038-48. [DOI: 10.1016/j.athoracsur.2008.05.013] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
21 Holmberg H, Elm T, Karpf D, Tranholm M, Bjørn SE, Stennicke H, Ezban M. GlycoPEGylated rFVIIa (N7-GP) has a prolonged hemostatic effect in hemophilic mice compared with rFVIIa: Letters to the Editor. Journal of Thrombosis and Haemostasis 2011;9:1070-2. [DOI: 10.1111/j.1538-7836.2011.04252.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
22 Gkiougki E, Mitsiakos G, Chatziioannidis E, Papadakis E, Nikolaidis N. Predicting Response to rFVIIa in Neonates With Intractable Bleeding or Severe Coagulation Disturbances. Journal of Pediatric Hematology/Oncology 2013;35:221-6. [DOI: 10.1097/mph.0b013e318286d27e] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
23 Ljung R, Karim FA, Saxena K, Suzuki T, Arkhammar P, Rosholm A, Giangrande P; The Pioneer™1 Investigators. 40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors. J Thromb Haemost 2013;11:1260-8. [DOI: 10.1111/jth.12237] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
24 Mathijssen NC, Masereeuw R, Holme PA, van Kraaij MG, Laros-van Gorkom BA, Peyvandi F, van Heerde WL. Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect. Thrombosis Research 2013;132:256-62. [DOI: 10.1016/j.thromres.2013.05.027] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
25 Rühl H, Berens C, Winterhagen FI, Reda S, Müller J, Oldenburg J, Pötzsch B. Increased Activated Protein C Response Rates Reduce the Thrombotic Risk of Factor V Leiden Carriers But Not of Prothrombin 20210G>A Carriers. Circ Res 2019;125:523-34. [PMID: 31314700 DOI: 10.1161/CIRCRESAHA.119.315037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
26 Négrier C, Abdul Karim F, Lepatan LM, Lienhart A, López‐fernández MF, Mahlangu J, Pabinger I, Li Y, Wolko D, Voigt C, Jacobs I, Santagostino E. Efficacy and safety of long‐acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery. Haemophilia 2016;22. [DOI: 10.1111/hae.12972] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
27 Jan J, Lin S, Lin C, Lee C, Fan S, Han Y. Recombinant activated factor VII as a promising adjuvant therapy for postpartum hemorrhage in the practice of obstetric anesthesia: Experience from a university hospital in Taiwan: Use of rAFVIIa to treat PPH. Journal of Obstetrics and Gynaecology Research 2011;37:901-7. [DOI: 10.1111/j.1447-0756.2010.01422.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
28 Mahmood I. Allometric extrapolation of factors VII, VIII and IX clearance in children from adults. J Thromb Haemost 2012;10:1609-13. [PMID: 22612736 DOI: 10.1111/j.1538-7836.2012.04787.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
29 Johansson L, Karpf DM, Hansen L, Pelzer H, Persson E. Activation peptides prolong the murine plasma half-life of human factor VII. Blood 2011;117:3445-52. [DOI: 10.1182/blood-2010-06-290098] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
30 Neufeld EJ, Saxena K, Kessler CM, Cooper DL; on behalf of the HTRS Investigators. Dosing, efficacy, and safety of recombinant factor VIIa (rFVIIa) in pediatric versus adult patients: The experience of the Hemostasis and Thrombosis Research Society (HTRS) Registry (2004-2008). Pediatr Blood Cancer 2013;60:1178-83. [DOI: 10.1002/pbc.24472] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
31 Gorkom BL, Holme PA, Joch C, Rogosch T, Feussner A, McKeand W, Roberts J, van Heerde W. Pharmacokinetics and pharmacodynamics of a recombinant fusion protein linking activated coagulation factor VII with human albumin (rVIIa-FP) in patients with congenital FVII deficiency. Hematology 2020;25:17-25. [PMID: 31852380 DOI: 10.1080/16078454.2019.1700329] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Shi R, Derendorf H. Pediatric Dosing and Body Size in Biotherapeutics. Pharmaceutics 2010;2:389-418. [PMID: 27721364 DOI: 10.3390/pharmaceutics2040389] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
33 Rühl H, Winterhagen FI, Berens C, Müller J, Oldenburg J, Pötzsch B. In vivo thrombin generation and subsequent APC formation are increased in factor V Leiden carriers. Blood 2018;131:1489-92. [DOI: 10.1182/blood-2017-12-823831] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
34 Grobler C, Callum J, Mccluskey SA. Reversal of vitamin K antagonists prior to urgent surgery. Can J Anesth/J Can Anesth 2010;57:458-67. [DOI: 10.1007/s12630-009-9250-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
35 Nichols TC, Dillow AM, Franck HW, Merricks EP, Raymer RA, Bellinger DA, Arruda VR, High KA. Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency. ILAR J 2009;50:144-67. [PMID: 19293459 DOI: 10.1093/ilar.50.2.144] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 4.0] [Reference Citation Analysis]
36 Bourti Y, Fazavana J, Armand M, Saller F, Lasne D, Borgel D, Bianchini EP. Inactivated antithrombins as fondaparinux antidotes: a promising alternative to haemostatic agents as assessed in vitro in a thrombin-generation assay. Thromb Haemost 2016;116:452-60. [PMID: 27412396 DOI: 10.1160/TH15-12-0927] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Erlandsson M, Nielsen CH, Jeppesen TE, Kristensen JB, Petersen LC, Madsen J, Kjaer A. Synthesis and characterization of 18 F-labeled active site inhibited factor VII (ASIS): Synthesis and characterization of 18 F-labeled ASIS. J Label Compd Radiopharm 2015;58:196-201. [DOI: 10.1002/jlcr.3282] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
38 Girolami A, Bertozzi I, de Marinis GB, Bonamigo E, Fabris F. Activated FVII levels in factor VII Padua (Arg304Gln) coagulation disorder and in true factor VII deficiency: a study in homozygotes and heterozygotes. Hematology 2013;16:308-12. [DOI: 10.1179/102453311x13085644680069] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]